FDA Approves Invega for Schizophrenia
View PDF | Print View
by: Guest
Total views: 63
Word Count: 254
On Wednesday, the Food and Drug Administration approved extended release Invega for the treatment of schizophrenia.
The approval was based on the results of 3, 6 week studies which were conducted in North America, Europe, Asia, and involved 1,665 participants. These studies concluded that Invega was more effective than a placebo for relieving symptoms associated with schizophrenia.
The patients in the group were given doses medication from 3 milligrams to 15 milligrams a day. Although minor, some of the side affects experienced by patients included restlessness, movement disorders, rapid heart beat, and sleepiness. Also, Invega belongs to the class of drugs called atypical antipsychotic which have been linked to an increased rate of death among elderly patients with dementia related psychosis. Thankfully this relates to a very small percentage of users.
This comes to good news to those suffering from schizophrenia. The National Institute of Mental Health states, “Schizophrenia is a chronic, severe, and disabling brain disorder that affects about 1 percent of people all over the world. People with schizophrenia sometimes hear voices others don’t hear, believe that others are broadcasting their thoughts to the world, or become convinced that others are plotting to harm them. These experiences can make them fearful and withdrawn and cause difficulties when they try to have relationships with others.”
According to Healthday, the FDA concluded that since the medication has not been tested for a period over 6 weeks, patients taking the medication long term should schedule regular visits to be monitored by a licensed physician.
Related: FDA Approves Invega for Schizophrenia
Additional information:
Foreign Pharmacies, Overseas Pharmacies, Internet Pharmacies, Online Pharmacy, and Foreign Pharmacy from Freebee Foreign.
Rating:
Not yet rated
Comments
No comments posted.
Add Comment
You do not have permission to comment. If you
log in, you may be able to comment.
